Biomendex OY
Biomendex is an innovative tissue engineering technology company based in Finland, dedicated to developing and manufacturing adaptable solutions for tissue regeneration, particularly in bone graft substitutes. Their mission is to give surgeons the freedom to operate and improve surgical outcomes through their versatile and bioactive products, including Adaptos® bone graft substitutes for clinical and veterinary use. The company emphasizes research, clinical trials, and collaborations with leading medical institutions to advance their technology and expand into new markets.
Industries
Nr. of Employees
small (1-50)
Biomendex OY
Korkeakoulunkatu 1, 33720 Tampere, Finland
Products
Adaptable synthetic bone graft substitutes for clinical use
Synthetic, biodegradable porous scaffolds designed to mimic cancellous bone structure and support bone regeneration in non-load-bearing applications; engineered for cutting, molding and packing in surgery.
Veterinary-grade adaptable bone graft substitutes
Veterinary line of the adaptable synthetic bone graft substitutes developed for clinical use in small animals, distributed through regional veterinary channels.
Adaptable synthetic bone graft substitutes for clinical use
Synthetic, biodegradable porous scaffolds designed to mimic cancellous bone structure and support bone regeneration in non-load-bearing applications; engineered for cutting, molding and packing in surgery.
Veterinary-grade adaptable bone graft substitutes
Veterinary line of the adaptable synthetic bone graft substitutes developed for clinical use in small animals, distributed through regional veterinary channels.
Services
Sponsorship and operational support for randomized, controlled clinical investigations for implantable bone graft substitutes, including trial setup and coordination with clinical partners.
Collaborative research projects with academic and clinical partners to validate materials, perform preclinical studies and develop application-specific solutions.
Establishment and management of distributor agreements and sales channel integration for veterinary and clinical products across multiple regions.
Sponsorship and operational support for randomized, controlled clinical investigations for implantable bone graft substitutes, including trial setup and coordination with clinical partners.
Collaborative research projects with academic and clinical partners to validate materials, perform preclinical studies and develop application-specific solutions.
Establishment and management of distributor agreements and sales channel integration for veterinary and clinical products across multiple regions.
Expertise Areas
- Bone tissue engineering
- Orthobiologics and scaffold development
- Porous scaffold fabrication and porosity optimization
- Preclinical testing and animal models
Key Technologies
- Supercritical CO2 foaming
- Ceramic-polymer composite scaffolds (β-TCP/polymer)
- Microcomputed tomography (micro-CT) and image-based modeling
- 3D porous scaffold design and porosity analysis
News & Updates
Biomendex collaborates with Mayo Clinic to further develop their fully synthetic and biodegradable bone graft material, Adaptos®, aiming for FDA approval in the U.S. market.
Biomendex and Biortho Ltd start collaboration to distribute Adaptos®Vet in China, South Korea, Thailand, and Malaysia.
Biomendex and N2 (UK) Ltd collaborate to distribute Adaptos®Vet in the UK and Northern Ireland, with purchase options through online stores and sales reps.
Biomendex raised 1 million euros to accelerate product development, clinical trials, and commercialization of Adaptos® bone grafts, supported by private investors, Business Finland, and EU Horizon 2020 funding.
Biomendex and Jorgensen Laboratories / Jorvet start collaboration to distribute Adaptos®Vet in the USA, Canada, and Mexico.
The European Union grants Biomendex up to €2.2 million to support clinical trials, production scaling, and market entry activities for Adaptos® over 24 months.
Biomendex collaborates with Mayo Clinic to further develop their fully synthetic and biodegradable bone graft material, Adaptos®, aiming for FDA approval in the U.S. market.
Biomendex and Biortho Ltd start collaboration to distribute Adaptos®Vet in China, South Korea, Thailand, and Malaysia.
Biomendex and N2 (UK) Ltd collaborate to distribute Adaptos®Vet in the UK and Northern Ireland, with purchase options through online stores and sales reps.
Biomendex raised 1 million euros to accelerate product development, clinical trials, and commercialization of Adaptos® bone grafts, supported by private investors, Business Finland, and EU Horizon 2020 funding.
Biomendex and Jorgensen Laboratories / Jorvet start collaboration to distribute Adaptos®Vet in the USA, Canada, and Mexico.
The European Union grants Biomendex up to €2.2 million to support clinical trials, production scaling, and market entry activities for Adaptos® over 24 months.